Overall market sentiment has been high on Vistagen Therapeutics Inc (VTGN) stock lately. VTGN receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With VTGN Stock Today?
Vistagen Therapeutics Inc (VTGN) stock is trading at $2.40 as of 12:04 PM on Tuesday, Jan 26, a loss of -$0.14, or -5.69% from the previous closing price of $2.55. The stock has traded between $2.34 and $2.65 so far today. Volume today is below average. So far 2,540,152 shares have traded compared to average volume of 4,175,196 shares.
To screen for more stocks like Vistagen Therapeutics Inc click here.
More About Vistagen Therapeutics Inc
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Click Here to get the full Stock Score Report on Vistagen Therapeutics Inc (VTGN) Stock.
